Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of Lsta1 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics和齊魯製藥宣佈齊魯在中國開展的針對轉移性胰腺導管腺癌患者Lsta1的2期試驗中首位患者接受治療
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of Lsta1 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics和齊魯製藥宣佈齊魯在中國開展的針對轉移性胰腺導管腺癌患者Lsta1的2期試驗中首位患者接受治療
使用瀏覽器的分享功能,分享給你的好友吧